Status:
COMPLETED
Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients
Lead Sponsor:
Assiut University
Conditions:
Hepatitis C
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
1. To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in chronic HCV infected patients in those with CKD versus ESRD in Assiut Hospital University . 2. Also assess duration of sustained viral...
Detailed Description
Hepatitis C virus (HCV) is a leading cause of liver disease worldwide, as 130-170 million individuals are chronically infected and 350,000 patients die every year from HCV infection. The HCV prevalenc...
Eligibility Criteria
Inclusion
- The patients aged from18- 60 years.
- Chronic HCV infection with Plasma HCV RNA greater than 15,000 IU/mL
- Treatment naïve.
- compensated liver cirrhosis.
- Absence of coinfection with HBV or HIV.
Exclusion
- Patients with hepatitis B virus or HIV.
- prior antiviral therapy.
- Haemoglobin level less than 10mg/dl.
- Decompensated liver disease.
Key Trial Info
Start Date :
November 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03341988
Start Date
November 22 2017
End Date
May 1 2018
Last Update
May 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt